Abbott Expects Xinlay Review By FDA Oncologic Drugs Advisory Cmte.
This article was originally published in The Pink Sheet Daily
Executive Summary
The company finished its rolling submission of the atrasentan application at the end of 2004, setting a fall 2005 user fee date. A Phase III trial of Xinlay in non-metastatic prostate cancer is ongoing, Abbott says.